28th Apr 2009 16:15
Results of the Annual General Meeting held on April 28, 2009
Dublin, Ireland - April 28, 2009 - Shire plc , the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
For* Against Withheld** 1. To receive the 385,589,148 2,271,000 26,380 Company's accounts together with the director's and auditor's reports 2. To approve the 307,647,526 60,796,610 19,442,392 Remuneration Report 3. To elect Dr Barry Price 356,441,471 31,425,618 19,439 as a Director of the Company 4. To re-appoint Deloitte 387,555,848 311,630 19,050 LLP as Auditors of the Company 5. To authorize the Audit, 387,180,598 671,746 34,184 Compliance and Risk Committee to determine the remuneration of the Auditors 6. To authorize the 332,997,412 54,868,377 20,739 allotment of shares 7. To authorize the 387,558,665 297,124 30,739 disapplication of pre-emption rights 8. To authorize market 387,693,316 173,212 20,000 purchases
* These figures include discretionary votes
** A vote "withheld" is not a vote in law and is not counted in the calculation of the votes "for" or "against" a resolution.
Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
Contact at Shire plc: Tony Guthrie, Deputy Company Secretary, 01256 894746
For further information please contact:
Investor Relations Cl©a Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 617 551 9715 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Jessica Cotrone (North America) +1 617 613 4640 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
2Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PXPress Release
www.shire.com
vendorRelated Shares:
Shire